Researchers developed a new algorithm that can use a single OCT scan to predict whether a patient with diabetic macular edema is likely to respond to anti-VEGF treatments. They tested it on pretreatment OCT images (top row) and used post-treatment OCT images (bottom row) to track response to treatment. Case 24 and 36 responded to treatment.
Credit: Sina Farsiu, Duke University
New algorithm poised to help doctors individualize treatment for diabetic macular edema
A new approach that uses artificial intelligence to analyze retinal images could one day help doctors select the best treatment for patients with vision loss from diabetic macular edema. This diabetes complication is a major cause of vision loss among working-age adults.
Anti-vascular endothelial growth factor (VEGF) agents are widely used as the first line of therapy for diabetic macular edema, but they don’t work for everyone. There’s a need to identify who would benefit from the therapy because it requires multiple injections that are costly and burdensome for both patients and physicians.
“We developed an algorithm that can be used to automatically analyze optical coherence tomography (OCT) images of the retina to predict whether a patient is likely to respond to anti-VEGF treatments,” said research team leader Sina Farsiu from Duke University. “This research represents a step toward precision medicine, in which such predictions help clinicians better select first-line therapies for patients based on specific disease conditions.”
In The Optical Society (OSA) journal Biomedical Optics Express, Farsiu and colleagues show that the new algorithm can analyze just one pre-treatment volumetric scan to accurately predict whether a patient is likely to respond to anti-VEGF therapy.
“Our approach could potentially be used in eye clinics to prevent unnecessary and costly trial-and-error treatments and thus alleviate a substantial treatment burden for patients,” Farsiu said. “The algorithm could also be adapted to predict therapy response for many other eye diseases, including neovascular age-related macular degeneration.”
Predicting treatment response
The algorithm developed by the researchers is based on a novel convolutional neural network (CNN) architecture, a type of artificial intelligence that can analyze images by assigning importance to various aspects or objects. They used the algorithm to examine images acquired with OCT, a noninvasive technology that produces high-resolution cross-sectional retinal images and is the standard of care for assessing and treating many eye conditions.
“Unlike previously developed approaches, our algorithm requires OCT images from only a single pretreatment timepoint,” said Reza Rasti, first author of the paper and a postdoctoral scholar in Farsiu’s laboratory. “There’s no need for time-series OCT images, patient records or other metadata to predict therapy response.”
The new algorithm preserves and highlights global structures in the OCT image while enhancing local features from diseased regions to efficiently use retinal thickness information. To help with treatment decision making, the researchers incorporated an additional step that looks for CNN-encoded features that are highly correlated with anti-VEGF response.
Testing the algorithm
The researchers tested their new algorithm with OCT images from 127 patients who had been treated for diabetic macular edema with three consecutive injections of anti-VEGF agents. They applied the algorithm to analyze OCT images taken before the anti-VEGF injections, then compared the algorithm’s predictions to OCT images taken after anti-VEGF therapy to confirm whether the therapy improved the condition.
Based on the results, the researchers calculated that the algorithm would have an 87 percent chance of correctly predicting who would respond to treatment. It exhibited an average precision and specificity of 85 percent and a sensitivity of 80 percent.
Next, the researchers plan to confirm and extend the findings from this pilot study by performing a larger observational trial of patients who have not yet undergone treatment.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Diabetic macular edema
- Oxular raises $37 millionon March 2, 2021 at 5:50 am
Oxular raises $37 million Led by specialist life sciences investor, Forbion Investment will fund Phase 2 human clinical studies evaluating Oxular’s 12-month treatment for diabetic macular edema, and ...
- Adverum Biotechnologies, Inc. (ADVM) Q4 2020 Earnings Call Transcripton March 2, 2021 at 4:31 am
Q4 2020 Earnings CallMar 1, 2021, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon, and welcome to the Adverum Biotechnologies ...
- Adverum Announces Shortened Timelines and Clear Development Path for ADVM-022 Intravitreal Gene ...on March 1, 2021 at 1:14 pm
REDWOOD CITY, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, ...
- Diabetic Macular Edema Market Up-to-date Industry Data on the Actual Market Situation, Trends, and Future Outlook 2025on February 28, 2021 at 8:38 pm
Mar 01, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry" “Diabetic Macular Edema Market” ...
- GRAding of functional and anatomical response to DExamethasone implant in patients with Diabetic Macular Edema: GRADE-DME Studyon February 26, 2021 at 6:53 am
To analyze functional and anatomical response patterns to dexamethasone (DEX) implant in diabetic macular edema (DME), to describe proportion of responders and non-responders, and to propose a new DME ...
Go deeper with Google Headlines on:
Diabetic macular edema
Go deeper with Bing News on:
Diabetes related vision loss
- Diabetes: watch out for these symptomson March 2, 2021 at 9:04 am
With that in mind, here are some of the symptoms of diabetes of which you should be aware. Unexplained weight loss Suddenly losing weight could ... about the issue for a full diagnosis. Blurred vision ...
- Identification of genetic factors influencing metabolic dysregulation and retinal support for MacTel, a retinal disorder | Communications Biologyon March 2, 2021 at 8:32 am
Melanie Bahlo and colleagues report a genome-wide association study on the retinal degenerative disease Macular Telangiectasia Type 2, identifying 8 new genome-wide significant loci. Further analyses ...
- Altai Balance Reviews - Effective Ingredients or Cheap Blood Sugar Pills? 2021 Reviewon February 26, 2021 at 7:07 pm
Altai Balance claims to “reset” your blood sugar, helping people with diabetes restore healthy blood sugar levels and resume living a normal life. Altai Balance Altai Balance claims to “reset” your ...
- Rapidly rising levels of sight loss are ‘tip of the iceberg’on February 24, 2021 at 7:41 am
According to research by the Vision Loss Expert Group, led by Professor Rupert Bourne of Anglia Ruskin University (ARU), issues such as glaucoma, sore eyes, conjunctivitis and diabetic retinopathy ...
- A Life with Diabetes ‘Complications’ Well Livedon February 22, 2021 at 8:08 am
What may strike you is his lack of self-pity or excuses; instead, he’s focused on the “miracles.” Before we dive into his life, there are some important things to know about diabetes complications — ...